Voyager Therapeutics (NASDAQ: VYGR) insider transactions
In the twelve months to 10 November 2026, executives and directors of Voyager Therapeutics reported 11 open-market sales of 80,209 shares ($297,957) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 November 2026 | Swartz Robin | President | Grant or award | +68,250 | — | 267,988 | Form 4 |
| 1 November 2026 | Carter Todd Alfred | Chief Scientific Officer | Grant or award | +33,000 | — | 178,718 | Form 4 |
| 2 April 2026 | Sandrock Alfred | President and CEO | Open-market sale, 10b5-1 plan | −11,511 | $3.87 | 472,549 | Form 4 |
| 1 April 2026 | Shiferman Gregory L. | SVP and General Counsel | Grant or award | +50,000 | — | 50,000 | Form 4 |
| 24 February 2026 | Carter Todd Alfred | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −4,174 | $3.76 | 145,718 | Form 4 |
| 24 February 2026 | Jorgensen Nathan D. | Chief Financial Officer | Open-market sale, 10b5-1 plan | −4,668 | $3.77 | 151,416 | Form 4 |
| 24 February 2026 | Sandrock Alfred | President and CEO | Open-market sale, 10b5-1 plan | −14,197 | $3.79 | 484,060 | Form 4 |
| 24 February 2026 | Swartz Robin | COO & Cbo | Open-market sale, 10b5-1 plan | −6,458 | $3.77 | 199,738 | Form 4 |
| 18 February 2026 | Sandrock Alfred | President and CEO | Open-market sale, 10b5-1 plan | −11,732 | $3.41 | 498,257 | Form 4 |
| 18 February 2026 | Carter Todd Alfred | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −3,301 | $3.44 | 149,892 | Form 4 |
| 18 February 2026 | Swartz Robin | COO & Cbo | Open-market sale, 10b5-1 plan | −3,882 | $3.44 | 206,196 | Form 4 |
| 10 February 2026 | Carter Todd Alfred | Chief Scientific Officer | Open-market sale | −3,525 | $3.85 | 153,193 | Form 4 |
| 10 February 2026 | Sandrock Alfred | President and CEO | Open-market sale | −12,192 | $3.78 | 509,989 | Form 4 |
| 10 February 2026 | Swartz Robin | COO & Cbo | Open-market sale | −4,569 | $3.85 | 210,078 | Form 4 |
| 6 February 2026 | Jorgensen Nathan D. | Chief Financial Officer | Grant or award | +32,250 | — | 156,084 | Form 4 |
| 6 February 2026 | Sandrock Alfred | President and CEO | Grant or award | +86,250 | — | 522,181 | Form 4 |
| 6 February 2026 | Swartz Robin | COO & Cbo | Grant or award | +45,000 | — | 214,647 | Form 4 |
| 6 February 2026 | Carter Todd Alfred | Chief Scientific Officer | Grant or award | +33,000 | — | 156,718 | Form 4 |
| 6 February 2026 | Ferguson Toby | Chief Medical Officer | Grant or award | +45,000 | — | 183,914 | Form 4 |
| 3 October 2025 | Jorgensen Nathan D. | Chief Financial Officer | Open-market sale, 10b5-1 plan | −7,666 | $4.78 | 123,834 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Voyager Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.